StemCell Therapy

The tooth is a biological organ and consists of multiple tissues including the cementum, dentin, enamel, and pulp. Dental caries, Periodontal disease, and tooth fracture are the three main factor for tooth loss. Tooth Regeneration is the specialty concerned with the treatment of dental diseases such as a cavity, periodontal disease and fracture of the tooth. Dental caries is also known as tooth decay is the main oral health problems in most of the industrialized countries. Facial trauma also the major cause of tooth loss. Tooth loss leads to people mentally and physically disturb and it also affect the self-confidence and quality of life. Tooth regeneration is the process of individual tissue and the whole tooth development. Basically, it is the process of restoring the loss of natural teeth. Tooth regeneration is stem cell-based regenerative medical procedure which is used in stem cell biology sector and tissue engineering. There are two approaches used in the build of new whole teeth, in vivo implantation of tooth germ cells which were previously generated from stem cells and grow in vitro cells and another organotypic culture is an appropriate technique for the generation of teeth. The process of tooth regeneration imitates the natural tooth development using stem cells. In another way instead of whole teeth regeneration, Different part of the teeth regenerates such as Enamel regeneration, Dentin regeneration, Pulp regeneration, and periodontal regeneration.

Globally increasing incidence and prevalence of dental problems such as a cavity, periodontal disease, and tooth fracture are the major factors driving the growth of the Tooth Regenerations market. Innovative new techniques in Tooth regeneration such as cell homing, cell transplantation is expected to increase the acceptance of Tooth Regenerations. Tooth regeneration not only regrowth the entire tooth but also the restoration of individual components of the tooth such as dentin, cementum, enamel and dental pulp and these individual regeneration process is anticipate the boost the market growth of tooth regeneration market. Dental implantation also increases the growth of tooth regeneration market. People are very keen interested in the tooth regeneration and they are also giving more importance to the aesthetic aspects of dental products, which is expected to increase the Tooth Regenerations and dental market over the forecast period. The increasing demand for a customized Tooth Regeneration with the specifications and other dental decorative installations is the key factor anticipated to propel the demand for Tooth Regenerations worldwide.

To remain ahead of your competitors, request for a sample [emailprotected]

https://www.persistencemarketresearch.com/samples/26263

The Global Tooth Regenerations market is segmented on the basis of application, Demographics, technique and by End user

Based on the Application type Tooth Regenerations market is segmented as:

Based on the Demographic Tooth Regenerations market is segmented as:

Based on the Technique, Tooth Regenerations market is segmented as:

Based on the end user Tooth Regenerations market is segmented as:

According to WHO, approx.30% the geriatric population is affected by the complete loss of teeth. Rapidly increasing Dental cavities and periodontal diseases are the major drivers in the Tooth Regenerations market. The global Tooth Regenerations market by application is expected to be dominated the market of Tooth Regenerations, out of which Enamel segment is expected to generate maximum revenue share over the forecast period. By end user, Tooth Regenerations market is expected to be dominated by dental clinics and hospitals. The manufacturers in the concerned market are focusing on manufacturing advanced products for better patient compliance and make the procedure easier. The market of tooth regeneration is anticipated to boost by stem cell regeneration technology

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/26263

The global Tooth Regenerations market is expected to be dominated by North America due to higher adoption and significant geriatrics population which also increase the demand for dental service for Dental caries and Periodontal disease. Europe is expected to be the second most lucrative Tooth Regenerations market due to rising funds for research for the growing patient population. Asia-Pacific is expected to be the fastest growing Tooth Regenerations market due to rapidly increasing incidence of dental surgery, general prosthetic fixation. Latin America and Middle East & Africa are expected to be the least lucrative market due to Low awareness regarding the use of Tooth Regenerations technology and comparatively less developed healthcare infrastructure in major regions.

Examples of some of the market participants in the global Tooth Regenerations market identified are DENTSPLY Implant, Unilever, Datum Dental, Institut Straumann AG, Keystone Dental, Inc., Zimmer Biomet, Wright Medical Group N.V., Integra LifeSciences, CryoLife, Inc, BioMimetic Therapeutics, Inc, Cook Group and among others.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

You Can Request for TOC Here @https://www.persistencemarketresearch.com/toc/26263

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Go here to see the original:
The end-use Industries to Help the Tooth Regenerations market stand in a good stead between 2018 and 2026 - The Daily Chronicle

I have a warm heart for our community. As a NEPA native, Im inspired by the ways The Wright Centers for Community Health and Graduate Medical Education and our larger community have navigated together this unprecedented and very challenging time of uncertainty caused by the COVID-19 pandemic. As a longtime, passionate primary care provider and medical educator, I am especially proud to be witnessing and experiencing the very best of what Ive always known about the noble profession of medicine: that the people maintaining the front lines of health care delivery do so for all the right reasons, striving to serve humanity with an abundance of courage, care and compassion, especially for the most vulnerable among us.

With World Heart Day coming up on Sept. 29, its important to acknowledge that although we dont know what the ongoing public health crisis still has in store for us, there is no doubt that taking care of ourselves and each other and promoting cardiovascular health are just as important as ever.

According to the World Heart Federation, cardiovascular disease is the No. 1 cause of death on our planet, and its primary causes are all too familiar to our regional community: smoking, diabetes, high blood pressure, sedentary lifestyles and obesity. Heart failure which happens when the heart fails to pump enough blood to the body and brain, resulting in symptoms like breathlessness, fatigue and swollen limbs affects 26 million worldwide and it is the top cause of hospitalization. Most concerning at this time is that people with underlying conditions, such as diabetes and heart disease, are most vulnerable to complications and death from COVID-19.

And yet one of the most troubling trends during the pandemic has been that many patients, including those with cardiovascular issues, have been avoiding routine medical care, preventative immunizations and even foregoing emergency room visits for fear of contracting the novel coronavirus within our healthcare systems.

Its absolutely critical that we tackle the double-edged threats cardiovascular disease and COVID-19 pose through raising awareness and promoting prevention and early detection, while offering reassurance. As everyone remains vigilant about staying safe and slowing transmission of the virus by wearing face masks, washing their hands frequently and continuing social distancing, I want to make sure the message is loud and clear that your primary care and specialty doctors offices and hospital emergency rooms are safe.

Please keep your health care on track, including timely acute and chronic disease management visits and also vaccination and cancer screening prevention services. The risks of undertreated hypertension and diabetes and untreated heart attacks and stroke far outweigh the risks of contacting COVID-19. And in times of cardiovascular troubles like heart attacks or strokes, every second counts.

The biggest keys to fighting cardiovascular disease education and prevention through healthy lifestyle behaviors are at the heart of two major Wright Center innovations aimed at enhancing the quality of and lengthening the lives of people in NEPA and across the country.

One is relatively brand new. Our Lifestyle Medicine initiative launched this summer as both a focused field of study for our resident doctors and fellows, as well as a key component of our patient-centered care for all routine clinical visits.

The other initiative is celebrating its 10th anniversary: our pioneering Cardiovascular Disease Fellowship, which launched in response to NEPAs well-documented cardiovascular health needs under the leadership of Dr. Samir Pancholy, with support from Geisinger, the Wilkes-Barre Veterans Affairs Medical Center and Commonwealth Health System.

Lifestyle Medicine encourages prevention by empowering patients to make better choices. We can look after our hearts and help to prevent cardiovascular disease by eating a healthy diet, saying no to tobacco and other risky substances, and getting plenty of sleep and exercise.

Our Cardiology Fellowship, meanwhile, trains doctors in community-based and hospital settings throughout Lackawanna and Luzerne counties. Over the course of their years in the program, fellows train one-on-one with our globally and nationally recognized, NEPA-based, board-certified cardiologists and cardiothoracic surgeons. Under our distinguished facultys guidance and on rotations through cardiac consultations, cardiac care units, cardiac catheterization and cardiovascular surgeries, our fellows acquire the knowledge and skills needed to provide state-of-the-art cardiac care, all while advancing our regional healthcare delivery system through their research projects and system improvement efforts.

The last decade of our Cardiology fellowship has produced a number of cardiac specialists who have stayed in NEPA to serve our community and to make meaningful contributions to our regions comprehensive care opportunities.

Celebrate World Heart Day by paying worthy attention to your self care and optimizing your cardiovascular health. Learn more about Lifestyle Medicine and the Million Hearts National Campaign. Most importantly, when you need help, reach out to your doctor and stay connected to other resources within our local health care community.

Linda Thomas-Hemak, M.D., a primary care physician triple board-certified in pediatrics, internal medicine and addiction medicine, leads The Wright Center for Community Health as CEO and serves as President of The Wright Center for Graduate Medical Education. She lives with her family and practices primary care in Jermyn. Send your medical questions to news@thewrightcenter.org.

See the original post here:
The Wright Medicine: Getting to the 'heart' of the matter - Valley Advantage

A monitor depicts the structure of SARS-CoV-2 during a Senate Health, Education, Labor and Pensions Committee hearing to discuss vaccines and protecting public health during the coronavirus pandemic on Capitol Hill, Wednesday, Sept. 9, 2020, in Washington. (Michael Reynolds/Pool via AP)

Researchers at the University of Pittsburgh School of Medicine said they have isolated a molecule that could be used as a treatment against COVID-19.

According to a report released earlier this week, the scientists isolated the smallest biological molecule that specifically neutralizes the virus that causes the virus.

The molecule has been used to create the drug Ab8 and has been viewed as a potential preventative treatment. Head researchers said the molecule is 10 times smaller than a regular sized antibody, which means it can penetrate into more areas of the body.

Its fully human, meaning that theres no foreign material thats likely to be rejected by the host, explained Dr. John Mellors, Division of Infectious Diseases at the University of Pittsburgh. Its extremely potent.

The molecule also doesnt bind to human cells, which suggests there would be no negative side effects. Researchers are also looking into different ways to administer the treatment and said it could be inhaled rather than injected.

Read more from the original source:
Researchers discover antibody molecule that could be used as preventative to COVID-19 - One America News Network

Rachel Roberts, Opinion contributor Published 6:16 a.m. ET Sept. 18, 2020

The rise of COVID-19 has understandably refocused our attention on health care access and inequities.One component that hasnt gotten as much attention, but should, is access to mental health care.Were in a moment where more of us than ever before could benefit from having an established relationship with a qualified provider.

Although we have seen sustained success in the fields of mental health care, counseling and addiction services in recent decades from gains in medicine to a more aware and understanding publicthe statistics are clear that this is not enough.

Indeed, two of the main drivers behind reports showing life expectancy is declining in the United States are the rising rates of drug addiction and suicide.The public has a good understanding of the importance of addressing the former, but comparatively less attention is given to how to spot and then stop someone from taking his or her life.

Related:Inequity in mental health care is yet another challenge facing the minority community

To understand suicides sizable scope, consider that its number here in the United States is four times higher than those murdered and a third larger than those killed in traffic accidents.Suicide rates are highest among adults between 45 and 64, and those with substance abuse disorders are six times more likely to commit suicide than those without, according toMental Health America.Worldwide, there are 800,000 suicides a year, or an average of one every 40 seconds.

I learned from an early age how much of a difference it makes when someone in crisis gets the care they need.My dad worked as an addiction specialist and had his office on the ground floor of our home.There were many times that I saw him open the door for clients who were struggling to survive, and there is no telling how many lives he and his friends in the field saved.

I will never forget the example he set, and it is one of the reasons why I proudly serve as a board member for Mental Health America of Kentucky andwhy improving access to mental healthand addictionservices across Kentucky is so important to me as a state legislator.

To further that goal, I am sponsoring legislation that would make what I think is a long-overdue change.I chose toannounceit Sept.10 to coincide with World Suicide Prevention Day and Suicide Prevention Awareness Month for our country.

Kentucky Rep. Rachel Roberts, a Democrat,represents District 67.(Photo: provided)

In short, my bill calls for comprehensive health insurance plans to include anannual preventative mental health checkup.

Just as we understand the importance of monitoring blood pressure and cholesterol and regularly visiting the dentist and eye doctor,we shouldcheck on our mental health in the same way.

If we want toprioritize mental health and well-being for all Kentuckians, were going to have to do more than we have done.There may be no single answer to get us to that destination, but my bill undoubtedly would move us in the right direction.

If you or someone you know is at risk of committing suicide, please do not hesitate to act.The National Suicide Prevention Lifeline is available 24 hours a day and can be reached at 800-273-8255.If it is an immediate emergency, please call 911.

Rachel Roberts, a Democrat,is a Kentucky representative forDistrict 67.

Read or Share this story: https://www.courier-journal.com/story/opinion/2020/09/18/kentucky-bill-would-help-increase-access-to-mental-health-care/5786847002/

Read more here:
With addiction and suicide on the rise, we must increase access to mental health care - Courier Journal

NEW YORK, Sept. 16, 2020 /PRNewswire/ --The Cura Foundation in collaboration with The Marcus Foundation, Sanford Health and Alliance for Cell Therapy Now, is supporting a clinical trial of human cord tissue mesenchymal stromal cells (hCT-MSC) to treat children with Multisystem Inflammatory Syndrome in Children (MIS-C). The trial is being led by Dr. Joanne Kurtzberg at Duke University to determine if infusions of hCT-MSCs are safe and can suppress the hyper-inflammatory response and positively impact the symptom course and duration, as well as the long-term effects of this life-threatening syndrome. The hCT-MSCs are manufactured in the Robertson GMP Cell Manufacturing Laboratory at Duke. The U.S. Food and Drug Administration (FDA) approved the Investigational New Drug (IND) Application, and Dr. Kurtzberg will proceed with a multi-site pilot study later this month.

As the school year is underway more children are being diagnosed with the SARS-CoV-2 virus. According to the American Academy of Pediatrics (AAP), the cumulative number of coronavirus cases diagnosed in children has more than tripled between July 2 and September 3 from 165,845 to 513,415. As of September 3rd, children represent at least 9.8% of diagnosed cases in the U.S. and in states such as Alaska, Minnesota, Tennessee, South Carolina, New Mexico and Wyoming, children account for more than 15 percent of total cases. Some of these children have developed very serious disease. The Centers for Disease Control and Prevention reported that as of September 3rd at least 792 children in 42 states have been diagnosed with Multisystem Inflammatory Syndrome in Children (MIS-C) and 16 have died.

The Principal Investigator of the study, Joanne Kurtzberg, MD, is the Jerome Harris Distinguished Professor of Pediatrics; Professor of Pathology; Director, Marcus Center for Cellular Cures; Director, Pediatric Blood and Marrow Transplant Program; Director, Carolinas Cord Blood Bank; Co-Director, Stem Cell Transplant Laboratory at Duke University School of Medicine/Duke Health and a leader in transplantation, cell therapy, and regenerative medicine in children. Clinical sites include Duke University (Durham, NC), Children's Healthcare of Atlanta (Atlanta, GA), New York Medical College (Valhalla, NY), and others as cases occur.

"We hope this is just the beginning of our ability to support the development of cell therapies to treat COVID-19 Related Multisystem Inflammatory Syndrome in Children," said Dr. Robin Smith,president of the Cura Foundation. "As students across the country return to in-class instruction, it is more important now than ever to ensure we are equipped with potential treatment options to care for children who develop this serious disease."

About the Sponsors

The Cura Foundationleads a global health movement with the goal to improve human health. Cura unites public and private sectors, partnering with doctors, patients, business leaders, philanthropists and thought leaders to create a collaborative network that tackles major health issues and accelerates funding to advance innovations in medicine. Cura believes that by encouraging interdisciplinary approaches to medicine, promoting preventative measures and advancing the development of breakthrough medical technologies you can improve access to care, streamline health care delivery and eliminate social disparities in health care. The Cura Foundation is a nonsectarian, nonpartisan, public and tax-exempt organization under Section 501(c)(3) of the Internal Revenue Code. For more information, please visit: https://thecurafoundation.org/

The Marcus Foundationwas founded in 1989 by Bernie Marcus, co-founder and former CEO of The Home Depot, to support programs in Children and Youth Development, Community, Free Enterprise, National Security, Veterans, Jewish Causes, Healthcare and Medical Research.

Sanford Health, one of the largest health systems in the United States, is dedicated to the integrated delivery of health care, genomic medicine, senior care and services, global clinics, research and affordable insurance. Headquartered in Sioux Falls, South Dakota, the organization includes 46 hospitals, 1,400 physicians and more than 200 Good Samaritan Society senior care locations in 26 states and 10 countries. Learn more about Sanford Health's transformative work to improve the human condition at sanfordhealth.orgor Sanford Health News.

Duke Healthconceptually integrates the Duke University School of Medicine, Duke-NUS Medical School, Duke University School of Nursing, Duke University Health System, Private Diagnostic Clinic (Duke physicians practice), and incorporates the health and health research programs within the Duke Global Health Institute as well as those in schools and centers across Duke University, including the Duke-Robert J. Margolis Center for Health Policy.

Duke Health is committed to conducting innovative basic and clinical research, rapidly translating breakthrough discoveries to patient care and population health, providing a unique educational experience to future clinical and scientific leaders, improving the health of populations, and actively seeking policy and intervention-based solutions to complex global health challenges. Underlying these ambitions is a belief that Duke Health is a destination for outstanding people and a dedication to continually explore new ways to help our people grow, collaborate and succeed.

Alliance for Cell Therapy Now(ACT Now) is an independent, non-profit organization devoted to advancing the availability of and access to safe and effective cell therapies for patients in need. ACT Now convenes experts and stakeholders to develop and advance sound policies that will improve the development, manufacturing, delivery, and improvement of regenerative cell therapies. Seehttp://allianceforcelltherapynow.org/

Contact

The Cura FoundationRobin Smith, MD, +1-212-584-4176[emailprotected]

SOURCE Alliance for Cell Therapy Now

allianceforcelltherapynow.org

More:
FDA Approves Study to Investigate the Use of Cell Therapy to Treat COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C) - PRNewswire

Decatur, GA DeKalb County Commissioner Lorraine Cochran-Johnson is partnering with Kaiser Permanente to host a special countywide town hall to share important information on how to stay healthy through the COVID-19 pandemic and upcoming influenza season, according to a press release from the county.

The Flu in an Era of COVID-19 Town Hall will take place Wednesday, Sept. 23, 2020, at 6 p.m. and will feature medical doctors that specialize in population health.

According the Centers for Disease Control and Prevention, there is a high probability that the flu and COVID-19 viruses will begin increasing in October and will spread this fall and winter. Commissioner Cochran-Johnson feels now is the time stress the importance of coupling education with preventative measures to avoid contracting both.

It is vital that we continue to stay steadfast in our efforts to decrease and ultimately stop the spread of COVID- 19, said Commissioner Cochran-Johnson. With flu season approaching, we must be equally intentional in educating the public on what to expect and how to stay healthy in the midst of this pandemic.

The Flu in an Era of COVID-19 Town Hall will educate DeKalb residents on the differences between the flu and COVID-19 and how they can affect each other, according to the press release from the county. In addition, residents will learn from medical experts how the flu and COVID-19 can impact ones mental and physical health, including pregnancies.

Presentations will be made by Dr. Chris Griffith (child, adolescent & adult psychiatrist & obesity medicine at Kaiser Permanente), Dr. Fatu Forna (physician program director for perinatal safety and quality at Kaiser Permanente), Dr. Belkis Pimentel (physician program director, quality performance and population health and flu expert at Kaiser Permanente) and Dr. Lynette Wilson-Phillips (pediatrician and co-medical director for Kids-Doc on Wheels).

COVID-19 and influenza are both respiratory illnesses that are contagious and have similar symptoms, however they are caused by different viruses and neither should be taken lightly, said Dr. Chris Griffith. Kaiser Permanente and its staff of medical professionals understand this and are dedicated to educating the public on the facts and how to stay healthy.

Decaturish.com is working to keep your community informed about coronavirus, also known as COVID-19. All of our coverage on this topic can be found at Decaturishscrubs.com. If you appreciate our work on this story, please become a paying supporter. For as little as $3 a month, you can help us keep you in the loop about what your community is doing to stop the spread of COVID-19. To become a supporter, click here.

Want Decaturish delivered to your inbox every day? Sign up for our free newsletter by clicking here.

See the rest here:
Dekalb County town hall will provide information about flu and COVID-19 - Decaturish.com

Demonstrating what is possible when working together to deliver higher quality care at lower costs, New Hanover Regional Medical Centers Medicare Shared Savings Program Accountable Care Organization (ACO), Physician Quality Partners (PQP), earned top scores in the latest data released by the Centers for Medicare & Medicaid Services (CMS).

PQP improved care for almost 20,000 Medicare beneficiaries in New Hanover and the surrounding counties, saving Medicare over $9.7 million by meeting quality and cost goals in 2019, according to recently released performance data from CMS, the federal agency that administers Medicare. PQP reduced the average cost of care by $501 per beneficiary.

PQP earned a quality score of 98.75 percent on performance measures ranging from preventive health checks, to use of electronic health records, to preventing avoidable hospitalizations, according to Medicare data.

Our work to improve care and quality while lowering costs within this group is just the beginning of what we can do to improve our regions health, said NHRMC President and CEO John Gizdic. By growing in our ability to provide new care options and access data that can be used to identify ways to improve care, we can help more people and lower overall costs.

The $9.7 million of gross savings to Medicare that PQP generated also resulted in a shared savings payment of $4.4 million to PQP, which will be used to help fund further investments in quality improvement and care management support to improve our beneficiaries health outcomes.

Partnering with our ACO providers is foundational in better serving patients, driving outcomes, and delivering value in this complex healthcare landscape, said Leelee Thames, MD, MBA, NHRMCs Chief Value Officer and ACO Medical Director. ACOs like ours are not only driving down costs, but most importantly, making remarkable improvements in the health and quality of life of our beneficiaries.

For example, PQP providers strive to improve long-term outcomes by directing efforts to services like annual wellness visits and evidence-based preventative screenings, known to impact disease conditions. The ACO also focuses on ensuring care is coordinated to ensure smooth transitions from the hospital to home or a nursing home if needed. All ACO providers receive detailed information about their performance on quality measures, and clinicians and providers share best practices to coordinate the care beneficiaries receive to prevent complications and repeat hospitalizations.

Through these efforts to improve outcomes, PQPs hospital admission rates dropped 17% and ED rates dropped 6.3% since the programs inception in 2016. Over the last year alone, PQP reduced unnecessary admissions and readmissions by over 2%, and Emergency Department visit rates by over 3%.

ACOs empower local physicians, hospitals and other providers to work together and take responsibility for improving quality, enhancing patient experience and keeping care affordable. The Medicare Shared Savings Program (Shared Savings Program) creates incentives for ACOs to invest in transforming care by allowing them to share in savings they generate after meeting defined quality and cost goals.

According to CMS, 541 Shared Savings Program participants generated $1.19 billion in total net savings to Medicare in 2019. ACOs continued to show improved or comparable quality performance on measures compared to other physician group practices.

The Medicare ACO shared savings program is the largest value-based payment model in the country and a critical tool in moving the health system toward higher value, said Lydia Newman, PQPs Executive Director.

PQP is a collaborative that includes the NHRMC Physician Group and Intracoastal Internal Medicine, an independent practice in Wilmington.

Founded in 2013, Physician Quality Partners (PQP) was created by New Hanover Regional Medical Center. The participating providers are united with the common goal of helping beneficiaries receive the right care, at the right time, in the right setting. In 2016, PQP began participating as a Tack 1 ACO in the Shared Savings Program and renewed participation on July 1, 2019 in the new Pathways to Success Model as a Track B participant.

To learn more about Physician Quality Partners, call 910-667-7640 or visit http://www.physicianqualitypartners.com.

You also can call 1-800-MEDICARE (1-800-633-4227), TTY users should call 1-877-486-2048 and tell the representative youre calling to learn more about ACOs or visit Medicare.gov/acos.html.

Sponsored content by

Read more here:
Physician Quality Partners generated $9.7 million in savings while improving care quality [Free read] - Port City Daily

The research led by Jeremy Wood, Zach Porterfield and Jamie Sturgill in the Department of Internal Medicine; Beth Garvy in Microbiology, Immunology & Molecular Genetics; and Wally Whiteheart in Molecular & Cellular Biochemistry, suggests localized inflammation in the lungs caused by COVID-19 may be responsible for the increased presence of blood clots in patients.

The study also provides evidence suggesting the risk of thrombosis could persist after the infection clears.

The study examined the blood of 30 COVID-19 patients including 15 who were inpatients in the intensive care unit, and 15 who received care as outpatients at UKs Infectious Diseases Clinic, along with eight disease-free volunteers who acted as a control group.

Compared to baseline, the COVID-19 patients had elevated levels of tissue factor, a protein found in blood that initiates the clotting process. Patients also had reduced levels of protein S, an anticoagulant that helps prevent blood clotting.

The researchers concluded that lung inflammation caused by COVID-19 is what leads to a decrease in protein S. Thisinflammation also causes immune and possible endothelial cell activation, which leads to increased tissue factor protein.

What weve learned is that the clotting is not caused by anything systemic. Localized inflammation in the lungs is whats driving this whole process, Wood said. With an increase in tissue factor and a deficiency in protein S, COVID-19 patients get more blood clotting without the ability to shut it down or control it.

The study additionally showed that protein S levels remained low in some patients even after they tested negative for COVID-19, which suggests that blood clotting issues may persist after infection and long-term monitoring of thrombotic risk may be necessary.

Wood says this preliminary data could be a cause for concern. Certain viruses like HIV are linked to a long-term deficiency in protein S, which causes an ongoing risk of thrombosis in patients. It is not yet known if COVID-19 could cause a similar persisting protein S deficiency.

Tissue factor and protein S are good markers to monitor for long-term thrombosis risk and the data suggest that we need to be monitoring these patients because were not seeing these parameters corrected immediately, Wood said.

The research team recently received a grant from UKsCenter for Clinical and Translational Science(CCTS) to begin a longitudinal study to look at these levels in patients over the next year.

This will help answer the question: will this risk remain like it is in the HIV patients or will it go away?

The study was funded in part by anAlliance Grantthrough the College of Medicine as well as UKsCOVID-19 Unified Research Experts (CURE) Alliancethroughthe Vice President for Research and the College of Medicine and the CCTS. It was a product of collaboration between a number of different groups at UK that have been studying COVID-19.

Additional collaborators includeMartha Sim, Meenakshi Banerjee and Hammodah Alfar in the Department of Molecular and Cellular Biochemistry; Melissa Hollifield and Jerry Woodward with Microbiology, Immunology and Molecular Genetics; Xian Li with the Saha Cardiovascular Research Center; Alice Thornton with the Division of Infectious Disease; and Gail Sievert, Marietta Barton-Baxter and Kenneth Campbell with CCTS.

The rest is here:
UK research getting to bottom of COVID clots - ABC 36 News - WTVQ

Deoxyribonucleic acid, or DNA as its usually called, has an appealing mystique. Its in our DNA is now a standard refrain for marketers and individuals trumpeting some essential virtue: honesty, courage, integrity, wholesomeness.

The hype is often misplaced, but undoubtedly DNA is a wondrous molecule with unique, amazing features.

DNA is the only molecule capable of reproducing itself. DNA is present in almost all living cells of all living things. Only DNA, and no other molecule, carries the ability to copy and then pass heritable information to subsequent generations. DNA is, indeed, the essence of life itself.

Despite these apparently magical tricks, DNA follows the ordinary laws of science and nature. Sometimes those rules are not obvious, but a little scientific digging and reliance on robust evidence will ferret them out.

Physically, DNA is a chemical in the form of a twisted, extendable ladder, the iconic double helix. The ladder is composed of rungs and sugar-phosphate siderails.

The rungs consist of a pair of the small chemical bases: adenine, thymine, cytosine, and guanine, abbreviated A, T, C, and G, respectively Crucially, adenine (A) pairs only with thymine (T), and cytosine (C) only pairs with guanine (G). Only the pairs of either A:T or C:G fit as rungs between the two siderails.

The DNA double helix, composed of nucleotide rungs and sugar-phosphate siderails Getty Images

The weight and structure of the DNA ladder naturally twists it into the double helix shape. And the ladder molecule can extend great distances. In a human cell, for example, the number of DNA bases pair rungs in the DNA runs over three billion, measuring over six feet in length.

However, in multicellular organisms like humans, the DNA does not remain as one long strand, but is cut and tightly packed into chromosomes.

Human DNA extracted as a single molecule from a single cell extends to just under two metres long, but is ordinarily segmented and stuffed into 23 pairs of chromosomes in each cell.

All bacteria, plants and animals, including humans, use DNA as the repository of their hereditary information. That is, the recipe to confer every genetic trait, from eye colour to blood type, is carried by segments of DNA stored within each cell of the organism. These DNA segments carrying genetic information are called genes, the root word of genetics.

What differs between human DNA and tomato DNA, or, for that matter, the DNA between two humans, is the precise sequence of DNA base pairs A, T, C, and G. By way of analogy, two different recipes in an English language cookbook may use the same 26 letters to make words but differ in the exact sequence of those same 26 letters, resulting in different recipes.

Read more about genetics:

Although DNA is physically the same double helix composed of long segments of A:T and C:G base pairs in all living things, the exact sequence of those bases varies from one organism to another. It is the order of bases that provides the instructions to produce, say, insulin in human pancreatic cells or photosynthetic enzymes in plants. A plants DNA lacks the base sequences instructions to make insulin, and human DNA lacks instructions for photosynthetic enzymes.

In any organism, such as a given human, the DNA in every cell has the same base sequence as every other living cell in that human.

The difference between a liver cell, and a skin cell is that while both activate (express) those genes required for basic living processes, the liver cell expresses those genes for liver proteins. Other genes remain present, but are not expressed. Meanwhile, skin cells express the genes unique to skin proteins, but liver (and other) genes are silenced.

The language of genetics is the same in all of life. A gene from any cell of any living thing can be copied, transferred and understood by any other living thing to make the same protein.

For example, human insulin is now made by microbes genetically engineered with the human DNA recipe for human insulin. That is, a copy of the human insulin gene is transferred to microbes, and those microbes read the human insulin gene recipe and make insulin, even though the microbes having no blood or blood sugar have no use for insulin. Similarly, most hard cheeses now are made with chymosin (a milk clotting enzyme) generated by genetically modified microbes.

From a scientific perspective, we can confidently state that life began at least once, about 3.5 billion years ago.

A more interesting question, scientifically, is Did life arise more than once?

Answer: unlikely. The evidence is based on DNA being the sole common feature of all living things. More importantly, the language DNA uses to convey information is common to all; the same language is read and understood by all living things. And most importantly, the DNA language is not just the common language used by all species; it is the only language used by any species.

There are no other languages of genetics.

When considering the number of potential languages DNA might have used instead, the fact that all known life forms use the same language of DNA to communicate the same information is compelling evidence that life arose only once.

The fact that all living things use DNA as their physical hardware, and share a single language of DNA as their intellectual software, is evidence that all living things derive from a common ancestor way back when.

Other evidence includes gene homology (a similar DNA base sequence of similar genes in diverse species) and a common synteny (the linear order of adjacent genes in the DNA of a chromosome).

The consensus in the scientific community is that life started once and that evolution provided our current diversity of living things. To be sure, scientists argue strenuously over the mechanics of evolution, and timing, and duration, and other minutia concerning evolutionary processes.

Nevertheless, these arguments do not challenge the scientific consensus: Evolution is real.

Curious humans have always been interested in heredity, pondering how children acquired the features of their parents. But scientists didnt learn that DNA carried the hereditary information until the mid 20th Century. And we didnt know the structure of DNA until 1953. And we didnt know how the genetic information was conveyed within the DNA molecule for some years after that.

More recently, molecular geneticists have learned not only how to read the information carried by a DNA strand, but also how to edit or supplement it. These innovations allow development of a number of commercial products such as the aforementioned insulin and cheese.

DNA is often in the news these days. But it wasnt always so popular. A series of events in the mid-1990s thrust DNA into the spotlight.

Colin Pitchforks murder trial in the UK and O J Simpsons murder trial in the USA sparked public interest in the forensic use of DNA.

Cloning of Dolly the sheep in Scotland raised the spectre of the technical feasibility of cloning humans, a science fiction nightmare.

Then came the appearance on our dinner plates of genetically engineered crops and foods, the fearsome genetically modified organisms, GMOs. All of these high-profile stories were based on the use or perhaps abuse of DNA.

Read more about DNA:

The rocketing popularity of DNA is reflected in the rise of direct-to-consumer DNA testing. For a relatively small fee, several companies will conduct a DNA analysis from the cells in your cheek swab or spit sample. However, these DNA tests are not 100 per cent accurate.

We are all genetically closer to our fellow humans than we might realise. All humans share over 99.9 per cent of their DNA base sequence, so all of the genetic differences between you and your neighbour, or between a Kalahari bushman and a Laplander, are attributable to just 0.1 per cent of the respective DNA.

Even so, the differences, although small, can have dramatic consequences. Your DNA sequence determines your basic blood type (A, B, AB, or O), hair and eye colour, whether your earlobes dangle, and whether you can roll your tongue.

Less trivially, your DNA sequence makes you more (or, if youre lucky, less) susceptible to certain types of cancer, heart disease, blindness, and over 200 other health-related conditions.

The best metaphor illustrating the information storage function of DNA is the encyclopedia of recipes.

Many people cherish their family recipe books handed down from ancestors. The secret, family recipes are sometimes supplemented or annotated, and then shared with children, generation after generation, thus perpetually preserving, albeit with minor changes, the familys culinary tradition.

In principle, the full complement of genetic information in an organism the genome is no different. The genome uses DNA instead of paper to convey the familys precious intellectual property. Our genome is like that multivolume family encyclopedia of recipes. A gene provides instructions and information to the cell, telling the cell to make specific proteins in specific tissues, at specific times, and under specific conditions.

Now, imagine your own family cookbook collection consisting of 23 volumes, with about 20,000 recipes in total, the approximate number of gene recipes in the human genome. We store most of our DNA in 23 pairs of chromosomes, for a total of 46 volumes in each cell. Each chromosome consists of a long DNA chain, with each metaphorical recipe corresponding to a shorter segment of DNA along the chain.

As scientists continue to study and understand DNA, they continue to innovate and devise practical applications.

Police now use DNA to identify long forgotten cold cases. Genealogists use DNA to compile and confirm family trees dating back centuries. Historians use DNA to identify the fragmented remains of lost soldiers, from WWI infantry missing in action at Vimy Ridge to King Richard III under a car park in Leicester.

Doctors use new drugs and medical treatments, including those to combat cancer and the coronavirus, developed from molecular genetic manipulation. And fertility experts help infertile couples have biological children. Understanding DNA and how it functions leads to new technologies while simultaneously enhancing our fascination with the molecule of life.

Still have questions? More on DNA and genetics:

Alan McHughens book, DNA Demystified: Unravelling the Double Helix, is out now (19.99, Oxford University Press).

Visit link:
Everything you need to know about DNA (almost) - BBC Focus Magazine

The Department of Biosciences and Nutrition performs research and education in several areas of medical science including aging, molecular endocrinology, cancer biology, functional genomics, systems biology, epigenetics, structural biochemistry, bioorganic chemistry, cellular virology, and nutrition. It offers an excellent international research and working environment, including around 250 scientists, students, administrative and technical personnel. The Department resides in the new biomedical research building Neo, aimed at being a creative and open environment that enables meetings, synergies, and exploration of areas of mutual interest across disciplines.

Do you want to contribute to top quality medical research?

Aging is one of the main risk factors for morbidity and mortality. Thus, a better understanding of the mechanisms that regulate this process is highly desirable. One of our efforts focuses on arguably the most important aging regulator known to date, the transcription factor DAF-16/FOXO. It resides downstream of the nutrient-sensing insulin/IGF signaling pathway and in response to low nutrients activates gene expression programs that slow down the aging process. DAF-16/FOXO depends on a diverse range of binding partners and regulators to fulfill its role, and we are studying their functions by diverse biochemical, genetic, and cytological techniques. (See Lin et al., Nature Communications 2018, or Sen et al., Nature Communications 2020, for examples of such work from our lab.)

Your mission

We are looking for a Postdoc to join our research group, the lab of Christian Riedel. Focus of this position is to explore a new binding partner of DAF-16/FOXO which we found to be required for DAF-16/FOXO to promote longevity in response to low nutrient signals. This work is conducted both in the model organism C. elegans and in human cells. You will synergize with aging biologists and bioinformaticians from the Riedel lab and be part of a larger aging-focused research environment at our department, which also contains the labs of Martin Berg and Maria Eriksson.

We are looking for a talented and highly motivated scientist with a doctoral degree and strong background in Molecular Biology, Cell Biology, Genetics, and/or Biochemistry. Good expertise in either C. elegans methods or in mammalian cell culture techniques is desired. Also, a background in the biology of aging is appreciated, even though it is not essential.

Applicants are expected to work independently but as part of an enthusiastic team and to be proficient in English. They are expected to play a leading role in the design and execution of their experiments as well as the analysis and the presentation/publication of the resulting data. Before and while being in the lab, the applicant will be encouraged to apply for competitive national and international postdoctoral fellowships and career grants and will receive support in those endeavors.

This position will be financed by a postdoc scholarship paid out by Karolinska Institutet.

Scholarships for postdoctoral qualification can be established for foreign researchers who place their qualifications in Sweden. The purpose of scholarships for postdoctoral qualification is to promote internationalization and contribute to research qualification after a doctorate or equivalent.A scholarship for carrying out postdoctoral research can be granted for a maximum of two years within a four year period following the receipt of a doctoral degree or equivalent.To be eligible for a postdoctoral scholarship, the person must have obtained a doctorate or a foreign degree deemed to be equivalent to a doctorate. Applicants who have not completed a doctorate at the end of the application period may also apply, provided that all requirements for a completed degree are met before the (intended) start date of the post doctoral education.

The head of the department determines whether their previous training and scholarly qualifications correspond to a Swedish doctorate or higher.

What do we offer?

A creative and inspiring environment full of expertise and curiosity. Karolinska Institutet is one of the worlds leading medical universities. Our vision is to pursue the development of knowledge about life and to promote a better health for all. At Karolinska Institutet, we conduct successful medical research and hold the largest range of medical education in Sweden.

Location: Department of Biosciences and Nutrition, Neo Building, Flemingsberg

Links: https://ki.se/en/bionut/department-of-biosciences-and-nutrition https://ki.se/en/bionut/christian-riedel-group http://riedellab.org/

The amount is tax free and it is set for twelve months at a time, paid out on a six months basis. In exceptional cases, shorter periods may be acceptable.

An application must contain the following documents in English:

You are welcome to apply at the latest by 16 October 2020.

The application has to be submitted through the Varbi recruitment system.

View post:
Postdoctoral studies on the molecular mechanisms that regulate aging - Nature.com

Rita Colwell is a pioneering microbiologist whose work on cholera helped illuminate the interplay between the environment and public health. She was also the first woman to serve as director of the National Science Foundation, and is currently a Distinguished University Professor at both the University of Maryland and Johns Hopkins Universitys Bloomberg School of Public Health.

In her half-century-plus in the sciences, Colwell has also seen very clearly the array of obstacles confronted by women as they try to navigate a traditionally male world. (When she applied for a graduate fellowship in bacteriology, she says was told, We dont waste fellowships on women.)

A Lab of Ones Own: One Womans Personal Journey Through Sexism in Science, by Rita Colwell and Sharon Bertsch McGrayne (Simon & Schuster, 288 pages).

Colwells new book, A Lab of Ones Own, co-authored with writer Sharon Bertsch McGrayne, documents much of what she has seen and heard over the years, from sexual harassment to the invisible structural obstacles placed in the way of women working in the sciences. (The books subtitle is One Womans Personal Journey Through Sexism in Science.)

Not long ago, women were discouraged from studying science at all; those who did pursue such studies were seen as oddities. Later, when the numbers of women earning science degrees began to rise, they found themselves receiving less funding than their male colleagues, and less likely to land a position as a professor or a lab director. (It wasnt that long ago, Colwell recalls, when a grant application could be turned down because a man on the granting committee simply didnt like women scientists.) But Colwell also found allies along the way, and her book is something of a celebration of what can be achieved when science strives for inclusivity.

The following interview has been edited for length and clarity.

UNDARK: Though sexism has a long history, you write that the 1950s and 60s saw unprecedented levels of sexism in the sciences. What was going on at that time?

Rita Colwell: The attitude was, a woman worked in the home period. A woman couldnt even get a credit card in her own name; she had to have her husband, or her father, vouch for her. In general, the understanding was, if you were [a woman] interested in science, that was peculiar. It wasnt unusual for women to go to college but most did not go from there into any kind of work, unless it was nursing or teaching. It was a very limiting time, for women. A lot of this was unspoken; it was just sort of assumed.

UD: Regarding graduate education, you say that women were simply seen as not worth investing in. What does that mean?

RC: The expectation was that you would get married and have children. If you werent there, with your children, you were seen as a bad mother. You went to college to find a husband; that was the expectation.

UD: You point out that not only could one face obstacles for being a woman Ph.D. student, you could face a backlash if you supervised too many women Ph.D. students. What was that about?

RC: The assumption was that anyone who was really brilliant, with great ideas, would work for a male professor. So if you took women students, it was assumed they werent the best and the brightest. Having women students would mark you as not serious; your students were just going to get married, and youre just wasting all this time.

UD: As you say, a lot of this was unspoken but eventually there was solid data to quantify this discrimination. How did that come about?

RC: It was in the 90s that Nancy Hopkins at MIT carried out her now-famous experiment: She measured the labs, and discovered that the men had almost twice as much space; they also got the bulk of the research money. More women were entering these careers [in the sciences], but men got most of the funding and most of the space.

Later, Jo Handelsman did the experiment where they sent identical letters to male researchers [from recent graduates applying to be a lab manager], the only difference was that some were signed John and others were signed Jennifer. The question was, would you hire this person, and what would you pay them? Far fewer said they would hire the woman; and the salary they were prepared to offer was much, much lower.

But Id like to emphasize one thing: Once I was able to break through, at each stage of my career, there was tremendous support. My father was very education-minded; it didnt matter if you were a girl or a boy; everyone went to school. My husband, a physicist, was a fantastic supporter; we were married for 62 very happy years. And my Ph.D. supervisor, John Liston, was absolutely the best. He was a newcomer to the University of Washington, starting a new program in marine microbiology so I ended up being the first graduate student with a Ph.D. in marine microbiology, possibly in the whole United States.

The assumption was that anyone who was really brilliant, with great ideas, would work for a male professor. So if you took women students, it was assumed they werent the best and the brightest.

UD: Youre known for your groundbreaking work on cholera, but it was also fascinating to read about your work investigating the 2001 anthrax attacks, in which a number of politicians and journalists were mailed packages containing the deadly substance in the weeks following the 9/11 attacks. How did you end up on the front lines of that investigation?

RC: I was appointed [as director of the National Science Foundation] by Bill Clinton, and I served two years under Clinton and four under George W. Bush. In October or November [of 2001], we heard about anthrax attacks. I remember saying, Weve got to sequence that bacterium, or well never know who did it.

I had been working on an advisory board for the CIA, so I was able to call on some colleagues, and we formed an inter-agency group. We decided not to make the group official, so that we could keep it a secret. And we worked for five years on this classified project. And using molecular genetics, we tracked down the source. Now, well never know whether the perpetrator was in fact Bruce Ivins, and if he worked alone, or with others. [Ivins died in 2008.] He was an anthrax microbiologist, and the source turned out to be in his lab.

UD: You were using a computer in the late 1950s, long before they became ubiquitous in the life sciences. Did you have a sense that computers would eventually impact every branch of science?

RC: At the University of Washington, I wrote a computer program the first in the country, for bacteriology using the old IBM 650, which has less power than the chip in your microwave oven. When I was working with that computer, I had to program it, and I didnt know diddly. But in my husbands lab, there was a postdoc named George Constabaris, who taught me. And there was another chap who was using the IBM to do pipe-fitting for the ships in Seattle harbor. He was programming how to cut and fit pipe most efficiently.

So it was clear to me that this was an amazing tool. I used the computer for taxonomic purposes, for identification which now everybody does. Its amusing I used to give talks about species of bacteria, and people would yawn. But now the hotshots in Silicon Valley know the differences between different kinds of bacteria. It was clear to me that we had to have massive computation [in the sciences]. I was able to get into the NSF budget, over my term, $2 billion, for computation, for universities to start building the internet railway, so to speak.

UD: So much has changed in science, and in the culture of science, over your career. Today, are you optimistic or at least, more optimistic?

RC: I would say its cautious optimism. I dont know whats going to happen in the next administration; it could be a disaster for women. I strongly encourage girls to go into science. I abhor the assumption that girls cant do math; its absurd. Or that if youre African American you cant do math or you cant do science its crazy. Theres still sexism, which ranges from the criminal to the clueless. Like when someone comments to a woman scientist as shes going up to the podium to give a talk, that she looks attractive. Thats the last thing you want to hear. You want to hear Thats a great idea, or Can we collaborate on the next stage of this experiment?

Read the original:
The Undark Interview: A Conversation with Rita Colwell - Undark Magazine

Patented CRISPRclean Technology is a Foundational Tool that Improves the Performance of Next-Generation Sequencing and Other Molecular Workflows by Increasing Sensitivity, Reducing Costs and Enabling Novel Discovery

CARLSBAD, CA, UNITED STATES - Sep 17, 2020 - Jumpcode Genomics - a genome technology company founded by industry veterans in 2016 focused on improving the understanding of human disease - today exited stealth mode and announced the commercial launch of its CRISPRclean technology. Initially available via three kits, CRISPRclean unlocks the power of next generation sequencing (NGS) by improving sensitivity, reducing costs and simplifying workflows. The company also announced that it has strengthened its leadership team with the addition of Yaron Hakak, Ph.D., as CEO. In addition, the company has added new advisors, including Dr. Stanley Nelson, vice chairman of Human Genetics at UCLA as consulting chief scientist, and Gary Schroth, Ph.D., vice president and distinguished scientist at Illumina, as a member of the companys scientific advisory board.

CRISPRclean technology is based on the in-vitro utilization of the CRISPR/Cas system to cleave and physically remove nucleic acid sequences pre- or post-NGS library preparation. This enables researchers to remove overabundant and uninformative sequences to allow discovery and detection of molecules previously undetectable (the needles). Like polymerase chain reaction (PCR), the technology broadly applies to many molecular biology techniques, particularly sequencing technologies.

Initial research applications focus on ribosomal RNA depletion, single cell analysis and repeat removal for whole genome sequencing. Additionally, Jumpcode Genomics is pursuing clinical applications, including the removal of human host molecules for a universal pathogen test and depletion of wild type alleles for somatic mutation detection in oncology. The technology seamlessly integrates into existing workflows and is agnostic to library preparation methods and sequencing platforms.

We aim to revolutionize the practice of molecular biology with our technology and to drive better results for researchers today and ultimately patients tomorrow, said Dr. Hakak, CEO of Jumpcode Genomics. When researchers perform NGS on biological samples, most molecules sequenced are uninformative, which results in a needle in a haystack problem. CRISPRclean solves this problem by simply removing the haystack.

The expansion of the leadership team and scientific advisory board enables Jumpcode Genomics to commercialize its technology and strengthen direct access to thought leaders in the scientific community.

About Jumpcode Genomics: Founded in 2016, Jumpcode Genomics aims to improve the understanding of human biology and the contribution to disease. The companys proprietary CRISPRclean technology utilizes the CRISPR/Cas system to deplete unwanted nucleic acid molecules from sequencing libraries. The process fits seamlessly within standard next generation sequencing workflows and works with most commercially available library preparation solutions. For more information, please visit: http://www.jumpcodegenomics.com

View post:
Jumpcode Genomics Exits Stealth Mode, Unveils Technology that Addresses the 'Needle in the Haystack' Problem of Molecular Biology - Bio-IT World

A team led by researchers from Case Western Reserve University School of Medicine and Cleveland Clinics Lerner Research Institute has secured $10.4 million over five years from the National Institutes of Health/National Cancer Institute to explore at the molecular level the differences in glioblastoma between males and females.

The researchers will delve into the genetics, epigenetics and cell biology of glioblastoma the most common and deadliest brain tumor in adults to better understand the physiologic processes which may lead to more personalized therapies.

The researchers have previously published research showing significant differences between the sexes in glioblastoma incidence, survival and some key molecular pathways. They found that glioblastoma is 60 percent higher in males than in females. In addition, females have a significant survival advantage over males with a median improved survival rate of up to 10 months. However, while these sex differences are understood, they are not yet considered when treating glioblastoma.

The research team is led by co-principal investigators Justin Lathia, Ph.D., of Cleveland Clinics Lerner Research Institute, and Jill Barnholtz-Sloan, Ph.D., of Case Western Reserve University School of Medicine. The team also includes colleagues from Penn State College of Medicine, Washington University School of Medicine in St. Louis, and the Translational Genomics Research Institute (TGen).

Glioblastomas are rare about 3.5-4 per 100,000 in the United States from 2012-16, the most recent data available from the Central Brain Tumor Registry of the United States (CBTRUS). Despite available treatments, glioblastomas have devastating consequences for patients. The median survival time is 12 to 14 months, and only about 5% of patients survive more than five years.

We have the molecular profiling technology and the computing and analytical strength to lead in this effort to better understand the role of sex differences in cancer, particularly for glioblastoma, said Barnholtz-Sloan, the Sally S. Morley Designated Professor in Brain Tumor Research and associate director of Data Sciences at the Case Comprehensive Cancer Center, Case Western Reserve School of Medicine. This next phase of research relies on vast, varied and complex datasets in animals and humans and promises to be a game-changer in how we understand the role of sex in tumor formation and disease outcomes. This comprehensive approach has applications to all forms of cancer, as well as other diseases.

Sex differences are inherent drivers of glioblastoma incidence and survival, and we are taking a multidimensional approach to uncover a better understanding of this differentiation, said Lathia, vice chair of the Department of Cardiovascular and Metabolic Sciences and co-director of the Brain Tumor Research & Therapeutic Development Center of Excellence at Lerner Research Institute, and co-leader of the Molecular Oncology Program at the Case Comprehensive Cancer Center. We are incorporating data from tumor cells and their surrounding micro-environment, as well as genetic programs responsible for tumor growth, and underlying epigenetic differences that may be responsible for sex differences. We aim to gain a better understanding of how these variables interrelate to better understand disease mechanism, which in turn defines better diagnostics and more personalized therapies for patients.

The multi-disciplinary project involves established investigators with complementary expertise and a strong collaborative history. Along with Lathia and Barnholtz-Sloan, participating institutions and their PIs include:

Three related research projects, undertaken by this collaborative team, will delve into the basic biology and cellular mechanisms that drive sex differences in glioblastoma formation and progression. These related research projects will inform, synergize and depend on each other. Findings from the labs based on their animal models will then be queried against data from human clinical samples across multiple institutions. The vast amount of data generated from these studies requires robust data management and sophisticated data analysis for a comprehensive view of sex differences across these diverse but related inquiries.

Comprehensive findings will inform future clinical research design, the search for targets for new therapeutics, or the use of existing therapeutics that may be applied differently depending on a patients sex.

This grant was made by the NIHs National Cancer Institute. Grant number: 1P01CA245705.

Cleveland Clinic: Alicia Reale, 216-408-7444, Realeca@ccf.org

Case Western Reserve: Bill Lubinger, 216-368-4443, william.lubinger@case.edu

The rest is here:
NIH Funds Research into Differences in Glioblastoma between Males and Females - Health Essentials from Cleveland Clinic

Published Study on Modifiable Risk Factors for the Emergence of Ceftolozane-Tazobactam Resistance

Presented Study on Long-Read Sequencing to Predict Phenotypic Antimicrobial Susceptibility Testing Results

Work Aimed at Demonstrating Diagnostic Value of Next-Generation Sequencing for Antimicrobial Susceptibility Testing and Translation into Clinical Practice

VIENNA, Austria and GAITHERSBURG, Md., Sept. 16, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, OpGen), announced today that scientists at its subsidiary Ares Genetics GmbH (Vienna, Austria; Ares Genetics), in collaboration with researchers from the Johns Hopkins University School of Medicine, have published a peer-reviewed study on modifiable risk factors for the emergence of ceftolozane-tazobactam resistance in P. aeruginosa in the journal Clinical Infectious Diseases.

P. aeruginosa is listed by the World Health Organization as critical priority pathogen. To overcome antimicrobial resistance, ceftolozane-tazobactam has been introduced as a novel -lactam--lactamase inhibitor combination agent and received initial U.S. FDA approval in 2014. While pre-clinical investigations indicated ceftolozane-tazobactam activity against approximately 85%-95% of U.S. and Canadian carbapenem-non-susceptible P. aeruginosa isolates, soon after the clinical introduction of ceftolozane-tazobactam, reports of resistance during therapy emerged.

The study published in Clinical Infectious Diseases sought to understand mechanisms of resistance leading to ceftolozane-tazobactam resistance, the frequency of cross-resistance between ceftolozane-tazobactam and other novel beta-lactam beta-lactamase inhibitor combinations and identify modifiable risk factors that may slow or prevent the acquisition of ceftolozane-tazobactam resistance. Findings demonstrate the potential of Next-Generation Sequencing (NGS) to investigate mechanisms of resistance by analyzing whole-genome sequencing data from P. aeruginosa isolates that developed resistance under treatment with ceftolozane-tazobactam. Mutations identified in ceftolozane-tazobactam resistant isolates involved, amongst others, AmpC, a known binding site for ceftolozane, PBP3, the target of ceftolozane, and DNA polymerase. The researchers propose extending ceftolozane-tazobactam infusions as a potential protective measure against acquired mutational resistance.

The present study is the result of an ongoing collaboration between Ares Genetics and the Johns Hopkins University School of Medicine, with the goal of investigating the diagnostic potential of NGS for antimicrobial susceptibility testing. Earlier this year, Dr. Patricia Simner of Johns Hopkins Medicine and Ares Genetics presented results from a study assessing the potential of long-read sequencing to predict antimicrobial susceptibility results at the online ASM Microbe 2020 meeting.

Dr. Andreas Posch, CEO Ares Genetics and co-author of both studies, commented, While we have already shown that NGS allows for CLIA-compliant identification of bacterial pathogens and antimicrobial resistance markers as well as accurate prediction of phenotypic resistance in previous publications, the present studies further underline the diagnostic value of NGS as well as the need for rapid antimicrobial resistance testing and improving antibiotic treatment regiments. I am particularly excited about our joint work on using long-read sequencing technology for phenotype prediction as this technology could potentially allow for molecular antibiotic susceptibility testing directly from native patient samples in just a few hours.

About OpGen, Inc.

OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGens product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

Story continues

For more information, please visit http://www.opgen.com.

Forward-Looking Statements by OpGen

This press release includes statements regarding studies and publications of OpGens subsidiary Ares Genetics GmbH. These statements and other statements regarding OpGens future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the realization of expected benefits of our business combination transaction with Curetis GmbH, the success of our commercialization efforts, the impact of COVID-19 on the Companys operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen Contact:Oliver SchachtCEOInvestorRelations@opgen.com

Press Contact:Matthew BretziusFischTank Marketing and PRmatt@fischtankpr.com

Investor Contact:Megan PaulEdison Groupmpaul@edisongroup.com

See the article here:
Collaborative Research by OpGen Group Company Ares Genetics and Johns Hopkins Researchers Demonstrates Potential of Next-Generation Sequencing for...

Data Bridge Market Research has recently published the Global research Report Titled Cardiovascular Genetic Testing Market. The study provides an overview of current statistics and future predictions of the Global Cardiovascular Genetic Testing Market. The study highlights a detailed assessment of the Market and displays market sizing trends by revenue & volume (if applicable), current growth factors, expert opinions, facts, and industry validated market development data.

Cardiovascular genetic testing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 4.01 billion by 2027 growing at a CAGR of 13.40% in the above-mentioned forecast period. An extensive array of employment of genetic experimentation in inherent disorders and oncology will prove advantageous for genetic testing business germination in the coming years.

FREE Sample Copy of Research Report Click Here: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cardiovascular-genetic-testing-market&utm_source=&kA

The Global Cardiovascular Genetic Testing Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Cardiovascular Genetic Testing market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Cardiovascular Genetic Testing Market in each region. Various methodological tools are used to analyze the growth of the worldwide Cardiovascular Genetic Testing market.

Top Key Vendors Covered in the report:

Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, QIAGEN, Pathway Genomics, Pacific Biosciences of California, Inc, Natera, Inc., Myriad Genetics, Inc., ICON plc, Laboratory Corporation of America Luminex Corporation, IntegraGen., HTG Molecular Diagnostics, Inc. , Genomic Health, Inc., Admera Health, deCODE genetics among other domestic and global players.

Regions included:

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, and Italy)

Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

South America (Brazil, Argentina, Colombia)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

How Does This Market Insights Help?

Key Pointers Covered in the Cardiovascular Genetic Testing Market Industry Trends and Forecast to 2026

Why choose us:

A complete value chain of the global Cardiovascular Genetic Testing market is presented in the research report. It is associated with the review of the downstream and upstream components of the Cardiovascular Genetic Testing Market. The market is bifurcated on the basis of the categories of products and customer application segments. The market analysis demonstrates the expansion of each segment of the global Cardiovascular Genetic Testing market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Cardiovascular Genetic Testing market.

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=global-cardiovascular-genetic-testing-market&utm_source=&KA

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Market Drivers

Market Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

For More Information or Query or Customization Before Buying, Click Here: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cardiovascular-genetic-testing-market&utm_source=&KA

Customization of the Report

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thanks for reading this article you can also get individual chapter wise section or region wise report versions like North America, Europe, MEA, or Asia Pacific.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rates

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

Read more here:
Cardiovascular Genetic Testing Market to Witness High Growth in Near Future and Competitive Analysis - The Daily Chronicle

The very first human beings originally emerged in Africa before spreading across Eurasia about 60,000 years ago. After that, the story of humankind heads down many different paths, some more well-studied than others.

Eastern regions of Eurasia are home to approximately 2.3 billion people today roughly 30% of the worlds population. Archaeologists know from fossils and artifacts that modern humans have occupied Southeast Asia for 60,000 years and East Asia for 40,000 years.

But theres a lot left to untangle. Who were the people who first came to these regions and eventually developed agriculture? Where did different populations come from? Which groups ended up predominant and which died out?

Ancient DNA is helping to answer some of these questions. By sequencing the genomes of people who lived many millennia ago, scientists like meare starting to fill in the picture of how Asia was populated.

In 2016, I joined Dr. Qiaomei Fus Molecular Paleontology Lab at the Institute of Vertebrate Paleontology and Paleoanthropology, Chinese Academy of Sciences in Beijing. Our challenge: Resolve the history of humans in East Asia, with the help of collaborators who were long dead ancient humans who lived up to tens of thousands of years ago in the region.

Members of the lab extracted and sequenced ancient DNA using human remains from archaeological sites. Then Dr. Fu and I used computational genomic tools to assess how their DNA related to that of previously sequenced ancient and present-day humans.

One of our sequences came from ancient DNA extracted from the leg bones of the Tianyuan Man, a 40,000-year-old individual discovered near a famous paleoanthropological site in western Beijing. One of the earliest modern humans found in East Asia, his genetic sequence marks him as an early ancestor of todays Asians and Native Americans. That he lived where Chinas current capital stands indicates that the ancestors of todays Asians began placing roots in East Asia as early as 40,000 years ago.

Farther south, two 8,000- to 4,000-year-old Southeast Asian hunter-gatherers from Laos and Malaysia associated with the Habnhian culture have DNA that, like the Tianyuan Man, shows theyre early ancestors of Asians and Native Americans. These two came from a completely different lineage than the Tianyuan Man, which suggested that many genetically distinct populations occupied Asia in the past.

But no humans today share the same genetic makeup as either Habnhians or the Tianyuan Man, in both East and Southeast Asia. Why did ancestries that persisted for so long vanish from the gene pool of people alive now? Ancient farmers carry the key to that answer.

Based on plant remains found at archaeological sites, scientists know that people domesticated millet in northern Chinas Yellow River region about 10,000 years ago. Around the same time, people in southern Chinas Yangtze River region domesticated rice.

Unlike in Europe, plant domestication began locally and was not introduced from elsewhere. The process took thousands of years, and societies in East Asia grew increasingly complex, with the rise of the first dynasties around 4,000 years ago.

Thats also when rice cultivation appears to have spread from its origins to areas farther south, including lands that are todays Southeast Asian countries. DNA helps tell the story. When rice farmers from southern China expanded southward, they introduced not only their farming technology but also their genetics to local populations of Southeast Asian hunter-gatherers.

The overpowering influx of their DNA ended up swamping the local gene pool. Today, little trace of hunter-gatherer ancestry remains in the genes of people who live in Southeast Asia.

Farther north, a similar story played out. Ancient Siberian hunter-gatherers show little relationship with East Asians today, but later Siberian farmers are closely related to todays East Asians. Farmers from northern China moved northward into Siberia bringing their DNA with them, leading to a sharp decrease in prevalence of the previous local hunter-gatherer ancestry.

Genetically speaking, todays East Asians are not very different from each other. A lot of DNA is needed to start genetically distinguishing between people with different cultural histories.

What surprised Dr. Fu and me was how different the DNA of various ancient populations were in China. We and others found shared DNA across the Yellow River region, a place important to the development of Chinese civilization. This shared DNA represents a northern East Asian ancestry, distinct from a southern East Asian ancestry we found in coastal southern China.

When we analyzed the DNA of people who lived in coastal southern China 9,000-8,500 years ago, we realized that already by then much of China shared a common heritage. Because their archaeology and morphology was different from that of the Yellow River farmers, we had thought these coastal people might come from a lineage not closely related to those first agricultural East Asians. Maybe this groups ancestry would be similar to the Tianyuan Man or Habnhians.

But instead, every person we sampled was closely related to present-day East Asians. That means that by 9,000 years ago, DNA common to all present-day East Asians was widespread across China.

Todays northern and southern Chinese populations share more in common with ancient Yellow River populations than with ancient coastal southern Chinese. Thus, early Yellow River farmers migrated both north and south, contributing to the gene pool of humans across East and Southeast Asia.

The coastal southern Chinese ancestry did not vanish, though. It persisted in small amounts and did increase in northern Chinas Yellow River region over time. The influence of ancient southern East Asians is low on the mainland, but they had a huge impact elsewhere. On islands spanning from the Taiwan Strait to Polynesia live the Austronesians, best known for their seafaring. They possess the highest amount of southern East Asian ancestry today, highlighting their ancestrys roots in coastal southern China.

Other emerging genetic patterns show connections between Tibetans and ancient individuals from Mongolia and northern China, raising questions about the peopling of the Tibetan Plateau.

Ancient DNA reveals rapid shifts in ancestry over the last 10,000 years across Asia, likely due to migration and cultural exchange. Until more ancient human DNA is retrieved, scientists can only speculate as to exactly who, genetically speaking, lived in East Asia prior to that.

[Understand new developments in science, health and technology, each week. Subscribe to The Conversations science newsletter.]

See the article here:
Ancient DNA is revealing the genetic landscape of people who first settled East Asia - The Conversation US

DetailsCategory: AntibodiesPublished on Friday, 18 September 2020 10:19Hits: 173

Agreement will significantly increase global supply capacity for Lilly's potential COVID-19 treatments

INDIANAPOLIS, IN and THOUSAND OAKS, CA, USA I September 17, 2020 I Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly's potential COVID-19 therapies. Lilly is currently studying several potential neutralizing antibodies for the prevention and/or treatment of COVID-19 as either monotherapy or in combination. Through this collaboration, the two companies will have the ability to quickly scale up production and serve many more patients around the world should one or more of Lilly's antibody therapies prove successful in clinical testing and receive regulatory approval.

"Based on our initial clinical studies, we believe that virus neutralizing antibodies, including LY-CoV-555, could play an important role in the fight against COVID-19," said Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories. "Increasing the manufacturing capacity for our neutralizing antibodies through this collaboration with Amgen is a crucial next step, and together we hope to be able to produce many millions of doses even next year."

"We are impressed with Lilly's data, in particular the reduction in hospitalizations, and are enthusiastic about the potential for these neutralizing antibodies as a therapeutic for COVID-19," said David M. Reese, M.D., executive vice president of research and development at Amgen. Esteban Santos, executive vice president of Operations at Amgen, added "we are proud to partner with Lilly and leverage our deep technical expertise in antibody development and, in particular, our strong capabilities in the scale up and manufacturing of complex biologics. This is yet another example of the ways our industry is closely collaborating to combat this devastating disease and help patients around the world access new therapies."

About AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visitwww.amgen.comand follow us onwww.twitter.com/amgen.

About Eli Lilly and CompanyLilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/news. C-LLY

SOURCE: Eli Lilly

Original post:
Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies | Antibodies | News Channels - PipelineReview.com

Two Yale research teams will each receive approximately $9 million in grants from the Aligning Sciences Across Parkinsons (ASAP) initiative to study the underlying biology of Parkinsons disease.

The ASAP grants, to be distributed over three years, are part of a major international, multi-institutional effort to uncover the basic disease mechanisms that drive the progressive neurological disorder, which afflicts 7 to 10 million people worldwide. The initiative builds and leverages a network of leading investigators, which will ultimately serve to promote rapid access to data, enabling breakthroughs across scales that will accelerate benefits for patients.

A Yale team headed byPietro De Camilli, the John Klingenstein Professor of Neuroscience, professor of cell biology, and investigator for the Howard Hughes Medical Institute, will study how gene mutations linked to Parkinsons affect the function of brain cells during the course of the disease. De Camilli will team with scientists from Weill Cornell Medicine to study the impact of Parkinsons disease on the physiology and metabolism of synapses, with the goal of identifying new therapeutic targets.

A second Yale team led byDavid Hafler, the William S. and Lois Stiles Edgerly Professor of Neurology and professor of immunobiology, will investigate whether the progression of Parkinsons disease pathology in the brain is initiated by an autoimmune process triggered by the gut microbiome. The research, part of the Center for Neuroinflammation at Yale, will leverage long-standing collaborations with researchers from Massachusetts General Hospital and the Broad Institute to produce an unprecedented map of the neuro-immune-gut interactions, with the goal of identifying new treatments for the disease.

The awards to two Yale teams illustrate the universitys dedication to collaborative science and the growing role Yale neuroscientists are playing in elucidating fundamental mechanisms of the most intractable conditions afflicting the brain and central nervous system, said Nancy J. Brown, dean of the Yale School of Medicine. Without a more robust understanding of basic mechanisms we cannot make progress in the treatment of Parkinsonism, she added.

Other Yale members of the De Camilli team areKarin Reinisch, the David W. Wallace Professor of Cell Biology and of molecular biophysics and biochemistry;Shawn Ferguson, associate professor of cell biology and neuroscience; andKallol Gupta, assistant professor of cell biology.

Other Yale members of the Hafler team areLe Zhang, assistant professor of neurology;Sreeganga Chandra,associate professor of neurology and neuroscience;Rui Chang,assistant professor of neuroscience;Noah Palm,assistant professor of immunobiology;Brian KooandJesse Cedarbaum, members of the clinical Department of Neurology; andDavid van Dijk, assistant professor in the Department of Medicine and Genetics.

ASAP is a coordinated research initiative dedicated to fostering collaboration and resources to better understand the underlying causes of Parkinsons disease. The Michael J. Fox Foundation is ASAPs implementation partner and issued the grants.

Read the rest here:
Yale teams get multi-million-dollar awards to study biology of Parkinson's - Yale News

PLAM BEACH, Fla., Sept. 16, 2020 /PRNewswire/ --The National Institute for Health (NIH) is at the heart of the emerging and rapidly evolving war against the global pandemic. They constantly update the public on the latest information on research for a vaccine and therapies to fight the virus. A recent report from them shone the light on a specific promising therapeutic approach nanomedicine. The NIH said that nanomedicine is a promising approach fordiagnosis, treatment and prophylaxis against COVID-19. They said that: "The COVID-19pandemic caused by the newly emerged severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) puts the world in an unprecedented crisis, leaving behind huge human losses and deep socioeconomic damages. Due to the lack of specific treatment against SARS-CoV-2, effective vaccines and antiviral agents are urgently needed to properly restrain the COVID-19 pandemic. Repositioned drugs such asremdesivir have revealed a promising clinical efficacy against COVID-19. Interestingly, nanomedicine as a promising therapeutic approach could effectively help win the battle between coronaviruses and host cells."Mentioned in today's commentary include: NanoViricides, Inc. (NYSE: NNVC), Immunomedics(NASDAQ: IMMU), Gilead Sciences, Inc. (NASDAQ: GILD), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Novavax, Inc. (NASDAQ: NVAX).

Due to a lack of approved vaccines and specific treatments only preventive measures can currently be applied. Currently, development of an effective vaccine and specific treatment is the main concern for researchers worldwide to fight the current COVID-19 and any future mutations. Understanding the coronaviral genome and the processes of viral replication and pathogenesis will enable researchers to develop specific drugs and vaccines. So researchers are turning to nanomedicine, one of the most important and emerging fields of modern science.

NanoViricides, Inc. (NYSE American: NNVC) Breaking News: NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 NanoViricides, a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program closer to human clinical trials.

The Company has accelerated its drug development program for COVID-19 with the goal of creating the most effective medicine to obtain regulatory approval for emergency use in the COVID-19 pandemic in the shortest timeline feasible, after achieving proof of concept of broad-spectrum anti-coronavirus effectiveness of test candidates. The Company therefore aggressively worked to harness the full power of the nanoviricides nanomedicine platform to achieve these objectives.

A curative treatment for a virus such as SARS-CoV-2 coronavirus would require a multi-faceted attack that shuts down (i) ability of the virus to infect host cells and simultaneously, (ii) ability of the virus to multiply inside the host cells. The nanoviricide platform enables direct multi-point attack on the virus that is designed to disable the virus and its ability to infect new cells. At the same time, a nanoviricide is also capable of carrying payload in its "belly" (inside the micelle) that can be chosen to affect the ability of the virus to replicate. The nanoviricide is designed to protect the payload from metabolism in circulation. Thus, the nanoviricide platform provides an important opportunity to develop a curative treatment against SARS-CoV-2, the cause of COVID-19 spectrum of pathologies.

The clinical candidate the Company has chosen is identified as NV-CoV-1-R. It is made up of a nanoviricide that we have found to possess broad-spectrum anti-coronavirus activity, now identified as NV-CoV-1, and remdesivir encapsulated inside the core of NV-CoV-1. NV-CoV-1 itself is designed to attack the virus particles themselves, and possibly would also attack infected cells that display the virus antigen S-protein, while sparing normal (uninfected) cells that do not display the S-protein. Additionally, remdesivir is widely understood to attack the replication cycle of the virus inside cells. Thus the combined attack enabled by NV-CoV-1-R on the virus could prove to be a cure for the infection and the disease, provided that the necessary dosage level can be attained without undue adverse effects. Human clinical trials will be required to determine the safety and effectiveness of NV-CoV-1-R.

Remdesivir is a well-known antiviral drug (developed by Gilead) that has been approved for emergency use treatment of SARS-CoV-2 infection or COVID-19 in several countries. NV-CoV-1 is a novel agent that is being used as an adjuvant to remdesivir in creating NV-CoV-1-R, to improve the overall effectiveness. It is well known that remdesivir suffers from rapid metabolism in circulation that breaks down the prodrug to its nucleoside form which is not readily phosphorylated. The Company anticipates that encapsulation in NV-CoV-1 may protect remdesivir from this rapid metabolism. If this happens, the effective level and stability of remdesivir in the body would increase. This increase may lead to increased effectiveness if there are no adverse effects. Such increased effectiveness, if found, may also allow reduction in the required dosage of remdesivir in the encapsulated form, i.e. as NV-CoV-1-R. In this sense, NV-CoV-1 can be viewed to act as an adjuvant that enhances the effect of remdesivir, a known antiviral against SARS-CoV-2.

"This is an extremely important milestone for the Company," said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, "We look forward to rapid development of the IND enabling core safety pharmacology studies and, thereafter, human clinical development on an accelerated timeline in these trying times of the pandemic." Read the full press release by going to: http://www.nanoviricides.com/companynews.html

In other biotech news in the markets this week:

Immunomedics(NASDAQ: IMMU) and Gilead Sciences, Inc. (NASDAQ: GILD)recently announcedthat the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion, was unanimously approved by both the Gilead and Immunomedics Boards of Directors and is anticipated to close during the fourth quarter of 2020.

The agreement will provide Gilead with TrodelvyTM(sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC) that was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in April for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Immunomedics plans to submit a supplemental Biologics License Application (BLA) to support full approval of Trodelvy in the United States in the fourth quarter of 2020. Immunomedics is also on track to file for regulatory approval in Europe in the first half of 2021.

"This acquisition represents significant progress in Gilead's work to build a strong and diverse oncology portfolio. Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat. We will now continue to explore its potential to treat many other types of cancer, both as a monotherapy and in combination with other treatments," said Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences. "We look forward to welcoming the talented Immunomedics team to Gilead so we can continue to advance this important new medicine for the benefit of patients with cancer worldwide."

INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, recently announced that Thermo Fisher Scientific, the world leader in serving science, has signed a letter of intent to manufacture INOVIO's DNA COVID-19 vaccine candidate INO-4800.

Thermo Fisherjoins other contract development and manufacturing organizations in INOVIO's global manufacturing consortium, enabling INOVIO to potentially scale commercial production of INO-4800. With its consortium of third-party manufacturers, INOVIO plans to have 1001million doses of INO-4800 manufactured in 2021, subject to FDA approval of INO-4800 for use as a COVID-19 vaccine.Thermo Fisherplans to manufacture INO-4800 drug substance as well as perform fill and finish of INO-4800 drug product at its commercial facilities in the US. At peak capacity,Thermo Fisherprojects that it could produce at least 100 million doses of INO-4800 annually.

Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, recently announced an amendment to its existing agreement with Serum Institute of India Private Limited (SIIPL) under which SIIPL will also manufacture the antigen component of NVXCoV2373, Novavax' COVID19 vaccine candidate. With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to overtwo billion doses annually, when all planned capacity has been brought online by mid-2021. NVXCoV2373 is a stable, prefusion protein made using Novavax' recombinant protein nanoparticle technology and includes Novavax' proprietary MatrixM adjuvant.

"Today's agreement with Serum Institute enhances Novavax' commitment to equitable global delivery of our COVID-19 vaccine. With this arrangement, we have now put in place a global supply chain that includes the recently acquired Praha Vaccines and partnerships with leading biologics manufacturers, enabling production on three continents," said Stanley C. Erck, President and Chief Executive Officer of Novavax. "We continue to work with extraordinary urgency to develop our vaccine, now in Phase 2 clinical trials, and for which we anticipate starting Phase 3 efficacy trials around the world in the coming weeks."

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated twenty five hundred dollars for news coverage of current press release issued by NanoViricides, Inc. by a non-affiliated third party.FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:Media Contact email: [emailprotected]+1(561)325-8757

SOURCE FinancialNewsMedia.com

Read more:
Nanomedicine Seen As A Promising Approach For Diagnosis and Treatment Against COVID - PRNewswire

Healthcare Nanotechnology Market2020-2025 report offerscomprehensive quantitative and qualitative market analysis. This report has been prepared under the continuous observation of the global market situation. This report has been formulated to give our clients the most up to date data and analyses of the Healthcare Nanotechnology Market. The impact on the enterprises and business development, distribution by region and global level is assessed in the report.

Top Companies are covering This Report:-

AmgenStrykerTeva PharmaceuticalsUCBRocheAbbottMerck & CoCelgeneBiogenSanofiLeadiant BiosciencesShireKyowa Hakko KirinGilead SciencesJohnson & Johnson3M CompanyEndo InternationalSmith & NephewPfizerIpsen

The research process involved the study of various factors affecting the industry such as government policy, market environment, competitive landscape, historical data, existing trends in the market, and market risks, opportunities, market barriers and challenges.

Reports Intellect projects Healthcare Nanotechnology Market based on elite players, present, past, and forecast data for the coming years which will act as a profitable guide for all the market competitors. The study includes growth trends, micro- economic and macro-economic indicators in detail and the report has been assessed with the help of PESTEL analysis and other essential analyses operating in the Healthcare Nanotechnology Market. Top-down and bottom-up approaches are used to validate the global Healthcare Nanotechnology market size and estimate the market size for Company, regions segments, product segments and Application.

Get Sample PDF Brochure @https://www.reportsintellect.com/sample-request/905451

The report offers all the essential data for players to secure a position of strength in the market, all while creating a comprehensive action plan. Our analysts here at Reports Intellect have used advanced primary and secondary research techniques to create the most up to date assessment of data on the Healthcare Nanotechnology Market which opens up a plethora of new opportunities to create new strategies to gain leverage over the competition.

Type Coverage:

NanomedicineNano Medical DevicesNano DiagnosisOthersNanomedicine has the highest percentage of revenue by type, with more than 86% in 2019.

Application Coverage:

AnticancerCNS ProductAnti-infectiveOthersAccording to the application, anticancer and CNS products accounted for 17.56% and 22.70% of the market in 2019 respectively.

Market Segment by Regions, regional analysis covers

North America Country (United States, Canada)

South America

Asia Country (China, Japan, India, Korea)

Europe Country (Germany, UK, France, Italy)

Other Country (Middle East, Africa, GCC)

Discount PDF Brochure @https://www.reportsintellect.com/discount-request/905451

Why us:

Reasons to buy:

About Us:-

Contact Us:

Sales@reportsintellect.com

PH + 1-706-996-2486

US Address:

225 Peachtree Street NE,

Suite 400,

Atlanta, GA 30303

Read more here:
Healthcare Nanotechnology Market Insights Competitive Analysis and Future Demand and Revenue Forecast to 2024 | Key Companies: Amgen, Stryker, Teva...